Hytrin

(terazosin)

PreclinicalSmall molecule

AAbbott

Hytrin is one of 40 small molecule programs targeting Urinary retention. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Urinary RetentionActive, not recruiting

Lower Urinary Tract SymptomActive, not recruiting

Urinary RetentionPreclinical

Active, not recruiting

Lower Urinary Tract SymptomPreclinical

Active, not recruiting

Competition

Competitive Landscape

40 competitors in Lower Urinary Tract Symptom

#DrugCompanyPhaseTrials

Flomax

Sanofi

Approved

5 2

Cialis

Eli Lilly

Approved

4 3

Vesicare

Astellas

Approved

4 4

Myrbetriq

Astellas

Approved

3 5

Rapaflo

AbbVie

Approved

2 6

Livial

Pfizer

Approved

1 7

Lioresal

Novartis

Approved

1 8

Uroxatral

AAdvanz Pharma

Approved

3 9

Detrol La

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—10

Tolterodine ER

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 2Not yet recruiting

Parkinson's Disease

NCT07464028

Phase 3Recruiting

Parkinson's Disease

NCT07207057

Clinical

Trials by Indication[1]

Parkinson's Disease4 trials

Terazosin Effect on Cardiac Changes in Early Parkinson's Disease

Active, not recruiting·—·Phase 2·NCT04386317·15 enrolled

A Pilot Study of Terazosin for Parkinson's Disease

Completed·JJordan Schultz·Phase 1/2·NCT03905811·13 enrolled

Terazosin And Metabolic Energetics in Parkinson's Disease

Not yet recruiting·NNandakumar Narayanan·Phase 2·NCT07464028·120 enrolled

Show 1 more trial

Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial

Recruiting·UUniversity College, London·Phase 3·NCT07207057·1,200 enrolled

Urinary retention1 trial

Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up

Terminated·HHospital Authority, Hong Kong·N/A·NCT00563485·120 enrolled

Antidepressants1 trial

Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin

Completed·TThomas Jefferson University·Phase 4·NCT00449683·23 enrolled

Motor Function1 trial

Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson's Patients

Not yet recruiting·II.R.C.C.S. Fondazione Santa Lucia·Phase 4·NCT05855577·50 enrolled

TED1 trial

Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms

Recruiting·PPenang Hospital, Malaysia·Phase 3·NCT06966804·150 enrolled

5 more indications

Adult1 trial

Target Engagement of Terazosin in Healthy Adults

Active, not recruiting·UUniversity of Iowa·Phase 1·NCT04551040·18 enrolled

Pilot Study1 trial

Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating

Completed·TThomas Jefferson University·N/A·NCT00237510·15 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting

Unknown status·—·Phase 2·NCT03195673·160 enrolled

Lower Urinary Tract Symptom1 trial

Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension

Completed·—·N/A·NCT00693199·360 enrolled

Vascular Function1 trial

Diesel Exhaust and Vascular Function

Unknown status·UUniversity of Washington·N/A·NCT01508637·24 enrolled

Regulatory

FDA Approval Timeline[4]

Aug 7, 1987

HYTRIN

NDA NDA019057

Dec 14, 1994

HYTRIN

NDA NDA020347

Jul 29, 2024

TEZRULY

NDA NDA218139

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for terazosin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — terazosin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for terazosin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA218139). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Hytrin. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Abbott company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAbbott

Patent Landscape[5]

Patent Cliff

Feb 1, 2041

Earliest patent expiration — generic entry possible after this date

Patent #Expires

12427108Feb 1, 2041

11224572Feb 1, 2041

Hytrin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Parkinson's Disease4 trials

Urinary retention1 trial

Antidepressants1 trial

Motor Function1 trial

TED1 trial

Adult1 trial

Pilot Study1 trial

Safety and Efficacy1 trial

Lower Urinary Tract Symptom1 trial

Vascular Function1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News